Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients.

about

Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients.

Item

http://www.wikidata.org/entity/Q55154129

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Combined assessment of the TNM ...... ic colorectal cancer patients.

@en

Combined assessment of the TNM ...... ic colorectal cancer patients.

@nl

type

Item

label

Combined assessment of the TNM ...... ic colorectal cancer patients.

@en

Combined assessment of the TNM ...... ic colorectal cancer patients.

@nl

prefLabel

Combined assessment of the TNM ...... ic colorectal cancer patients.

@en

Combined assessment of the TNM ...... ic colorectal cancer patients.

@nl

P1476

Combined assessment of the TNM ...... dic colorectal cancer patients

@en

P2093

Alberto Orfao

http://www.w3.org/2001/XMLSchema#string

Jacinto García

http://www.w3.org/2001/XMLSchema#string

Jose Antonio Alcazar

http://www.w3.org/2001/XMLSchema#string

José María Sayagués

http://www.w3.org/2001/XMLSchema#string

Juan Jesús Cruz

http://www.w3.org/2001/XMLSchema#string

Marcos González

http://www.w3.org/2001/XMLSchema#string

María Angoso

http://www.w3.org/2001/XMLSchema#string

María Del Mar Abad

http://www.w3.org/2001/XMLSchema#string

María Fernanda Anduaga

http://www.w3.org/2001/XMLSchema#string

María Jesús Baldeón

http://www.w3.org/2001/XMLSchema#string

P2860

Fast and accurate short read alignment with Burrows-Wheeler transform

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Cancer statistics, 2015

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

P304

24081-24096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25300

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29844874

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5963609

http://www.w3.org/2001/XMLSchema#string